Home ›
Lymphoma Trials ›
NCT04961515
Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
This phase II trial is evaluating the efficacy and side effect of orelabrutinib, sintilimab and temozolomide as possible treatments for relapsed or refractory central nervous system lymphoma.
Trial Details
NCT ID NCT04961515
Phase PHASE2
Sponsor Second Affiliated Hospital, Zhejiang University, School of Medicine
Status RECRUITING
Cancer Type Lymphoma
Interventions Orelabrutinib Sintilimab Temozolomide (TMZ)
Locations (sample) Hangzhou, Zhejiang, China|30.29365,120.16142
Key Eligibility Criteria
Histologically documented primary central nervous system(CNS) lymphoma or secondary diffuse large B-cell lymphoma (DLBCL) isolated to CNS. Relapsed or refractory disease with at least 1 prior methotrexate-based therapy Participant must be able to understand and willing to sign a written informed consent document. Participant must have signed and dated written informed consent form in accordance with regulatory and institutional guidelines. This must be obtai…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →